clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Kv1.3 channel blocker, the most common co-covered peer. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Zealand Pharma
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Kv1.3 channel blocker, the most common co-covered peer. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Biotech story that mention Zealand Pharma, all published on February 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Zealand Pharma. Shared-story counts are live from our verified record — not editorial picks.
Zealand Pharma has announced positive topline results from its Phase 1a trial of ZP9830, a novel Kv1.3 channel blocker. The study successfully met its primary objectives for safety and tolerability, paving the way for further development of this oral candidate for chronic inflammatory and autoimmune diseases.